Oligo Medic

Was founded in 2010 by pioneers of chitosan as a material for biomedical applications, with over 25 years of experience developing medical devices.

 

Their earlier efforts culminated in the commercialization of BST-CarGel, a cartilage repair product acquired by Smith&Nephew. 

 

Initially focused on its novel technology platform, Oligo Medic has developed a fully self-gelling injectable scaffold for cartilage repair. The company rapidly reached commercialization milestones for its first product JointRep including CE mark in 2014.

 

By 2021 there had been over 7000 patients treated in over 20 countries spanning Canada, Europe, Australia/New Zealand, Southeast Asia and Latin America. Growth potential for the JointRep platform includes use of JointRep for other body joints than the knee, and use of JointRep as a carrier for biologics (PRP, stem cells, etc.).

 

Oligo Medic operates under a Quality Management System compliant with the requirements of ISO13485:2016. 

joint.png

Submitted package to FDA in May to initiate JointRep® trial in the United States

2020

Obtained license from TGA for JointRep® in Australia.

2019

Obtained license from Health Canada for JointRep®.

2018

Gaining market penetration in Europe, ANZ regions, South East Asia, and Latin America

2018

Preliminary steps taken toward procedures with FDA for market approval in the US.

2018

Very favorable results on clinical trial published in Journal of Clinical Orthopedics and Trauma.

2018

Initiated European controlled clinical trial comparing microfracture to microfracture + JointRep®.

2015

Initial experimentation with JointRep® and microfracture. Results are highly favorable with fast pain relief, accelerated recovery time, and nice cartilage regrowth.

2014

Obtained CE mark in October. Structured OligoMedic for distribution partnership and initiated case studies and post market evaluation.

2013

Follow up case series on Health Canada SAP.

2011

Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep® operation.

2010

Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep® operation.

2010

Manufacturing, packaging, and shipping processes defined.

2012

Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep® operation.

2010

Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep® operation.

2010

Timeline

Initiating large-scale JointRep® RCT study in Australia, New Zealand & Canada to demonstrate quantitative MRI evidence of superiority of cartilage repair tissue, supporting existing clinical findings & outlook for long-term clinical outcomes.

2021

Obtained license from TGA for JointRep® in Australia.

2019

Gaining market penetration in Europe, ANZ regions, South East Asia, and Latin America

2018

Initiated European controlled clinical trial comparing microfracture to microfracture + JointRep®.

2015

Obtained CE mark in October. Structured OligoMedic for distribution partnership and initiated case studies and post market evaluation.

2013

Follow up case series on Health Canada SAP.

2011

BST-CarGel gets CE mark

2012

Development of BST-CarGel begins: multiple pre-clinical publications

2000

BST-Gel discovered & patented: first polysaccharide-based thermogel

1998

BioSynTech founded by Dr. Amine Selmani. (BSY was founded as a spin-off from Ecole Polytechnique de Montréal).

Product concepts defined in three new categories: chronic wounds, ophthalmology & spine. Development gracefully supported by MEI, MEDTEQ+ & NSERC.

2021

Obtained license from Health Canada for JointRep®.

2018

Very favorable results on clinical trial published in Journal of Clinical Orthopedics and Trauma.

2018

Initial experimentation with JointRep® and microfracture. Results are highly favorable with fast pain relief, accelerated recovery time, and nice cartilage regrowth.

2014

Manufacturing, packaging, and shipping processes defined.

2012

Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep® operation.

2010

BST-CarGel clinical trial begins

2004

Seminal BST-Gel publication in Biomaterials: 1000+ citations to date

2000

The "World's first " discovery of the gelling properties of the Chitosan buffered solution at Ecole Polytechnique de Montréal.

1995

1995